Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia.
Pediatr Blood Cancer
; 68(1): e28739, 2021 01.
Article
en En
| MEDLINE
| ID: mdl-33009894
ABSTRACT
Chimeric antigen receptor (CAR) T-cells, engineered autologous T-cells that target antigens found in leukemia, have shown durable remissions in relapsed acute lymphoblastic leukemia (ALL). Infant ALL with KMT2A rearrangements (KMT2Ar) is a rare, aggressive form of leukemia associated with extramedullary disease both at diagnosis and at relapse, and overall outcomes for these patients are dismal. Here we report the successful use of tisagenlecleucel, a CAR T-cell product approved for relapsed/refractory ALL, in a patient with KMT2Ar infant ALL who was treated for combined marrow and extramedullary (renal) relapse.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Inmunoterapia Adoptiva
/
Neoplasias de la Médula Ósea
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Receptores Quiméricos de Antígenos
/
Neoplasias Renales
/
Recurrencia Local de Neoplasia
Tipo de estudio:
Prognostic_studies
Límite:
Female
/
Humans
/
Infant
Idioma:
En
Revista:
Pediatr Blood Cancer
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Año:
2021
Tipo del documento:
Article